Vomikind

Ondansetron

Method of action: Anti-Abstinence, Antiemetic

Treatment option: Acute Nausea And Vomiting, Cancer, Burping, Morning Sickness, Chemotherapy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vomikind

What is Vomikind? The Definition and Pharmacological Class

The following overview provides a concise summary of the drug Vomikind (Ondansetron), defining its core identity, composition, and general purpose as an anti-nausea medication.

Property	Description
Active ingredient	Ondansetron
Form	Tablet, Injection, Syrup, Oral solution
Pharmacological class	Selective 5-HT3 receptor antagonist
Common use	Anti-nausea and anti-vomiting agent
Origin	Synthetic compound

Vomikind is a prescription medicine categorized as an antiemetic agent, primarily used to control and prevent episodes of severe nausea and vomiting. This brand, manufactured by Cipla, is a single-ingredient product whose sole active ingredient is Ondansetron, often available chemically as Ondansetron hydrochloride dihydrate. The drug is formally classified within the pharmacological class of selective 5-HT3 receptor antagonists, distinguishing it as a highly targeted therapy among anti-sickness treatments. Ondansetron is a standard therapeutic option for controlling severe emesis.

Composition and Available Pharmaceutical Forms

The core of Vomikind is the synthetic compound Ondansetron, which is provided to patients in a variety of pharmaceutical preparations suitable for both oral and parenteral routes of administration. These dosage form(s) include the conventional tablet and the orally disintegrating tablet (ODT), alongside liquid options such as syrup and oral solution. Its high-level composition consists of the active ingredient Ondansetron combined with inert pharmaceutical excipients or an aqueous base vehicle. As a carbazole derivative, Ondansetron’s origin is entirely synthetic, ensuring precise chemical purity.

Vomikind's General Purpose: Interrupting the Vomiting Signal

The general purpose of Vomikind is to provide reliable and focused relief by chemically interrupting the body's vomiting reflex when triggered by physiological stress. Its unique mechanism principle involves the selective antagonism of the 5-HT3 receptors, which are key receivers for the chemical messenger serotonin in the digestive tract and the brain's chemoreceptor trigger zone (CTZ). By blocking these receptors, the drug prevents the message that initiates nausea and vomiting from reaching the brain, offering effective control over these distressing symptoms. The primary role of this class of drugs is to prevent nausea and vomiting signals by blocking specific serotonin action.

Regulatory References

MedlinePlus Ondansetron Drug Information

What side effects are possible with Vomikind?

Possible Side Effects and Safety Information

The safety profile of Ondansetron (Vomikind) is documented by governmental regulatory agencies by classifying adverse reactions according to their frequency and the physiological system affected. This structure provides a descriptive overview of documented risks, without offering clinical advice or instructions for use.

Adverse Reaction Classifications

Side effects are categorized based on their official rate of occurrence, reflecting data from clinical studies and post-marketing surveillance:

Very Common: Headache.
Common: Constipation, flushing or sensation of warmth, and dizziness. Injection site reactions are common with parenteral (injection) forms.
Uncommon: Seizures, hypotension (low blood pressure), bradycardia (slow heart rate), and involuntary body movements (extrapyramidal reactions).
Rare: Arrhythmias (irregular heartbeat), including ventricular and supraventricular events, and transient visual disturbances, which are primarily reported during or shortly after intravenous administration.

System and Serious Safety Concerns

Adverse reactions are documented across several System-Organ Classes, notably Nervous System Disorders (including headache and seizures) and Cardiac Disorders (including arrhythmias and bradycardia).

Serious Adverse Reactions officially listed in regulatory documents include the risk of QT Interval Prolongation, a dose-dependent cardiac safety concern that can lead to Torsades de Pointes. The label also documents the risk of Serotonin Syndrome when used concomitantly with other serotonergic medicines, and instances of severe hypersensitivity reactions, including anaphylaxis.

Safety Restrictions and Limitations

Use of Ondansetron is subject to specific regulatory limitations. The medicine is contraindicated in patients with documented congenital long QT syndrome due to the risk of serious cardiac events. It is also contraindicated for use with apomorphine. Furthermore, individuals with severe hepatic impairment are noted to have significantly increased systemic exposure, necessitating a restriction on the maximum daily exposure.

Overdose and Emergency Response

Vomikind Overdose and when to seek help

The official regulatory profile for an overdose of Vomikind (Ondansetron) focuses on immediate clinical risks and mandated emergency actions. Overdose manifestations documented in prescribing information primarily affect the cardiovascular and neurological systems.

Documented Manifestations	Description
Cardiovascular Effects	May include hypotension, fast heart rate (tachycardia), and various arrhythmias. The most severe risk is marked QT interval prolongation, which can lead to the life-threatening ventricular arrhythmia Torsades de Pointes.
Neurological Effects	Symptoms such as seizures or convulsions, syncope (fainting), and episodes of temporary amaurosis (blindness), which typically resolve, have been reported. Severe constipation has also been documented.

Required Emergency Actions

In the event of a suspected overdose, immediate medical attention must be sought. Due to the potential for delayed and serious cardiac effects, continuous ECG monitoring is required until the patient is clinically stable. Treatment is strictly symptomatic and supportive, as official labeling states that no specific antidote is known for Ondansetron overdose. For massive overdose cases, regulatory documents note the potential for airway obstruction and confirm that dialysis is not anticipated to be effective.

Therapeutic Uses of Vomikind

Vomikind is a medicine that contains the active substance ondansetron and is utilized to address or prevent feelings of nausea and the physical act of vomiting.

The primary uses involve managing these symptoms in specific clinical contexts:

Chemotherapy-Associated Nausea and Vomiting: It is administered to reduce the risk of nausea and vomiting that may occur as a consequence of cancer chemotherapy treatments.
Radiation Therapy-Associated Nausea and Vomiting: The medication is used to help control nausea and vomiting linked to radiation therapy, particularly when targeting the abdomen.
Postoperative Nausea and Vomiting (PONV): It is indicated to mitigate the onset of nausea and vomiting following surgical procedures, which can be related to the effects of anesthesia.

This medication is a tool to support comfort and promote well-being during these treatments.

Quick Facts

Therapeutic Domain: Nausea and Vomiting Management
Key Usage Areas: Chemotherapy-associated nausea, Radiation-induced nausea, Postoperative nausea
Clinical Goal: To help control the sensation of sickness and the act of vomiting.

Eligibility and Restrictions for Use

Absolute Contraindications

Use of Vomikind is contraindicated (prohibited) in populations explicitly identified in regulatory labeling. This includes patients receiving concomitant apomorphine due to the risk of severe hypotension and those diagnosed with congenital Long QT syndrome due to the risk of serious arrhythmia. The medicine is also contraindicated in individuals with a known history of hypersensitivity to ondansetron or any component.

Restricted and Age-Based Eligibility

Specific limitations are applied based on patient status. Individuals with severe hepatic impairment must not exceed a maximum total daily dose of 8 mg, as defined by official regulatory guidance. For patients with Phenylketonuria (PKU), the orally disintegrating tablet (ODT) formulation is restricted.

Age-based eligibility is established for managing chemotherapy-induced nausea and vomiting (CINV) in children 6 months and for postoperative nausea and vomiting (PONV) in children 1 month (IV form).

Pregnancy and Lactation Status

Official regulatory documents advise that use is not recommended during the first trimester of pregnancy. Additionally, mothers are advised not to breastfeed while using this medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns of the active ingredient, Ondansetron, as recognized by government regulatory agencies.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type	Interacting Substances and Official Restrictions
Contraindicated Combination	Co-administration with Apomorphine is strictly prohibited due to the documented risk of severe hypotension and loss of consciousness.
Pharmacokinetic Modifiers	Concomitant use with strong enzyme inducers (e.g., Phenytoin, Carbamazepine, Rifampicin) may cause a substantially decreased plasma concentration of Ondansetron by increasing its clearance.
Pharmacodynamic Augmentation	The official label notes an increased risk of Serotonin Syndrome when used with other serotonergic drugs (e.g., SSRIs, SNRIs, Tramadol). Additionally, co-administration with other QT-prolonging agents (e.g., Amiodarone) increases the risk of cumulative effects on cardiac rhythm.

Mechanism of Action

Vomikind (Ondansetron) functions through a precise molecular mechanism that modulates the neural signaling within the emetic reflex arc at two distinct sites, with the mechanism defined by the blockade of a specific neurotransmitter receptor.

Selective Blockade of the 5-HT3 Receptor

The core mechanism involves acting as a highly selective antagonist of the Serotonin type 3 receptor (5-HT3), which is a ligand-gated ion channel. By binding to this receptor, the drug prevents the endogenous neurotransmitter serotonin (5-HT) from triggering the channel to open. The functional consequence of this action is the inhibition of the nerve cell's ability to generate an action potential.

Dual Interruption of the Emetic Signal Cascade

The drug’s action occurs simultaneously in two vital anatomical locations: at the vagal afferent nerve terminals in the gastrointestinal tract and centrally in the brain's Chemoreceptor Trigger Zone (CTZ). This dual blockade interrupts the transmission of the neural signal from both peripheral sources (the gut) and central sources (the bloodstream), thereby preventing the necessary input signals from reaching the medullary Vomiting Center for the coordination of motor output.

Mechanism Specificity and Pathway Limitations

The mechanism is strictly confined to pathways mediated by the 5-HT3 receptor. This high selectivity is a functional constraint that dictates the mechanism is active only when serotonergic signaling is the dominant neural pathway. Consequently, this specificity constrains the modulation of neural pathway activity driven primarily by other neurochemical systems, such as those involving histamine or muscarinic receptors.

Dosage and Administration Information

Official Administration Guidelines for Vomikind (Ondansetron)

Vomikind (Ondansetron) is an antiemetic prescribed for use via the oral route (tablet, orally disintegrating tablet (ODT), or solution) and the parenteral route (intravenous (IV) or intramuscular (IM) injection). The official administration schedule is strictly prophylactic, meaning the medicine must be given prior to the emetogenic event (chemotherapy, radiation, or surgery) to be effective.

Standard Adult Dosing Regimens

Dosing is standardized based on the severity of the emetogenic trigger:

Clinical Context	Dosage Regimen (Adult)	Timing/Frequency
Highly Emetogenic Chemotherapy	Single 24 mg oral dose	30 minutes before chemotherapy
Postoperative Nausea & Vomiting (PONV) Prophylaxis	Single 16 mg oral dose	1 hour before anesthesia
Continuation Oral Therapy	8 mg twice daily (every 12 hours)	For 1 to 2 days after event

Procedural and Population Constraints

The total duration of use for oral continuation therapy is generally limited to a short course of 1 to 5 days, depending on the regimen. Oral tablets may be administered with or without food, while Orally Disintegrating Tablets (ODTs) are designed to dissolve on the tongue without water.

For patients with severe hepatic impairment (Child-Pugh score ge 10), the total maximum daily dose must not exceed 8 mg, regardless of the route of administration. For intravenous use, doses greater than 8 mg must be diluted and infused slowly over a minimum period of 15 minutes. No alteration of dosage or frequency is generally required for patients with renal impairment.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Mechanism of Action

Vomikind (active ingredient ondansetron) is a serotonin 5-HT3 receptor antagonist. This means it works by blocking the action of serotonin on certain nerve endings, particularly those in the gastrointestinal tract and the area of the brain responsible for triggering vomiting (the chemoreceptor trigger zone, or CTZ).

Evidence in Chemotherapy-Induced Nausea and Vomiting (CINV)

Numerous randomized controlled trials (RCTs) have examined the role of ondansetron in preventing CINV. Research indicates that when used alone or in combination with other antiemetics, ondansetron is a key component in guidelines for controlling both acute (within 24 hours) and delayed (1-5 days later) CINV. Studies have evaluated the drug's effectiveness against various emetogenic (nausea-inducing) chemotherapy regimens, including those categorized as moderately and highly emetogenic.

Evidence in Postoperative Nausea and Vomiting (PONV)

Meta-analyses and large-scale studies have consistently assessed ondansetron's effectiveness in preventing and treating PONV. Research suggests that administration of the drug at the end of surgery is associated with a reduction in the incidence of nausea and vomiting in the immediate postoperative period compared to placebo.

Special Populations

Research has explored the use of ondansetron in other groups, including children and patients undergoing radiation therapy. Evidence suggests that for both groups, the drug is used for managing nausea and vomiting related to these medical procedures, with dosing adjusted according to patient weight and procedure type.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Vomikind (FAQ)

Q: Can Vomikind be taken 'as needed' or does it need to be scheduled?

Vomikind is primarily intended for scheduled use, such as taking it before an event (prophylaxis) or for short-term continuation therapy. Official patient instructions describe regimens that include scheduled use for prophylaxis, but regulatory guidance may also provide options for when to take a dose outside of a strict schedule if symptoms occur.

Q: Can Vomikind be crushed or chewed if someone has trouble swallowing pills?

The standard Vomikind tablet is described in official documents as needing to be swallowed whole with liquid. If an individual has difficulty swallowing pills, the orally disintegrating tablet (ODT) formulation is specifically designed to dissolve quickly on the tongue without the use of water.

Q: Are there specific symptoms that mean I should stop taking Vomikind and seek medical help?

Official product information documents list several serious adverse reactions that require prompt medical attention. These include signs of a severe allergic reaction (like swelling of the face or sudden difficulty breathing), an irregular heartbeat, or symptoms that match Serotonin Syndrome. These warnings are present to document the potential for serious, rare events and indicate when prompt medical attention may be needed.

Q: How quickly does Vomikind typically start to work after taking it?

According to patient-focused information derived from regulatory documents, the active ingredient, Ondansetron, typically begins to show its effect within about 30 minutes after it is taken orally.

Q: What is the average duration of action for Vomikind?

The dosing schedule for continuation therapy often involves taking the medicine twice daily, or every 12 hours. This frequency suggests that the effect of a single dose lasts for an extended period, which informs the time interval for the next dose in official guidelines.

Q: Is it common to feel a little sleepy after taking Vomikind?

While not listed as a very common side effect in all official documents, tiredness or drowsiness has been reported. Some clinical trial data also note a general feeling of malaise or fatigue as an adverse reaction in a percentage of users.

Q: Can older people (seniors) use Vomikind safely?

Based on official regulatory reviews of studies, no overall differences in safety or effectiveness were observed between subjects aged 65 years and older and younger subjects. Appropriate studies have not demonstrated problems specific to the geriatric population that would limit the usefulness of this medicine.

Q: What happens if I forget to take a scheduled dose of Vomikind?

Official guidance regarding a missed dose typically describes options such as taking the dose if remembered, or skipping the missed dose if it is close to the time of the next scheduled dose. This guidance helps maintain the intended dosing interval.

Q: Does taking Vomikind affect the results of any common medical tests?

The official product information notes that Vomikind may cause changes to the results of certain medical tests, specifically those related to liver function. This effect has been documented, though it is considered uncommon unless the medicine is taken with certain other chemotherapy drugs.

Q: What does official data say about Vomikind use in people with pre-existing gastrointestinal conditions?

Regulatory labels contain a specific caution for patients who have gastric distension (an enlarged or swollen stomach). This is because the medication works to prevent vomiting, which could potentially cover up the symptoms of an existing stomach or intestinal problem.

Q: Are there special warnings about operating machinery while using Vomikind?

Official patient information leaflets often include a caution regarding activities that require alertness, such as driving or operating heavy machinery. This warning is included because certain side effects, like dizziness, are commonly reported while using this medicine.

Q: Why does Vomikind sometimes cause a feeling of malaise or unease?

The reason for this feeling is related to its documented safety profile. Malaise, which is a general feeling of discomfort or unease, has been officially listed in clinical trial data tables as a reported adverse reaction.

How should Vomikind be stored and disposed of?

How to Store and Dispose of Vomikind (Ondansetron)

Storage Requirements

Vomikind (Ondansetron) must be stored at Controlled Room Temperature, which is typically defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container to maintain its stability.

Mandatory storage conditions require the product to be protected from both light and moisture. For safety, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

All unused or expired Vomikind must be disposed of in accordance with local regulations. If official take-back programs are unavailable, the FDA recommends mixing the medicine with an undesirable substance, such as dirt or used coffee grounds, placing the mixture in a sealed container, and disposing of it in the household trash. It is officially advised not to flush this medication down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.